Red-Cell Aplasia Due to Antibodies against Human Recombinant Erythropoietin (rHuEPO) in a Peritoneal Dialysis Patient Treated with rHuEPO

Eschbach JW , Adamson JM . Modern aspects of the pathophysiology of renal anemia. Contrib Nephrol 1988; 66:63–70.

Eschbach JW , Varma A , Stinelman JC . Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anemia? Nephrol Dial Transplant 2002; 17(Suppl 5):2–7.

Eschbach JW . Erythropoietin 1991 — an overview. Am J Kidney Dis 1991; 18:3.

Paganini EP , Eschbach JW , Lazarus JM . Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis 1995; 26:331.

Lundin AP . Eritropoyetina recombinante e insuficiencia renal crónica. Hospital Pract (ed Esp) 1991; 6:57–66.

Macdougall IC . Novel erythropoiesis stimulating protein. Semin Nephrol 2000; 20:375–81.

National Kidney Foundation. DOQI guidelines: anemia of chronic kidney disease. III. Iron support: guidelines 5–10, Part I-II. Available from: URL: http://www.uptodate.com

Drüeke T , Eckardt KU . Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patients. Nephrol Dial Transplant 2002; 17 (Suppl 5):28–31.

Macdougall IC , Cooper A . The inflammatory response and epoetin sensitivity. Nephrol Dial Transplant 2002; 17(Suppl 1):48–52.

Donnelly SM . Bioavailability of iron in hemodialysis patients treated with erythropoietin. Evidence for the inhibitory role of aluminum. Am J Kidney Dis 1990; 16:447.

Albitars S , Genin R , Feu-Chong M . High dose enalapril impairs the response to erythropoietin treatment in hemodialysis patients. Nephrol Dial Transplant 1998; 13:1206.

Krantz SB . Pure red-cell aplasia. N Engl J Med 1974; 291:345–50.

Fisch P , Handgretinger R , Schaefer HE . Pure red cell aplasia. Br J Haematol 2000; 111:1010.

Palmieri G , Lastoria S , Colao A , Vergara E , Varella P , Biondi E . Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J Med 1997; 336:263–5.

Lacy MQ , Kurtin PJ , Tefferi A . Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996; 87:3000–6.

Schett G , Firbas U , Füreder W , Hiesberger H , Winkler S , Wachauer D . Decreased serum erythropoietin and its relation to anti-erythropoietin antibodies in anaemia of systemic lupus erythematosus. Rheumatology 2001; 40: 424–31.

Sipsas N , Kokori SI , Ioannidis JP , Kyriaki D , Tzioufas A , Kordossis T . Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia. J Infect Dis 1999; 180: 2044–7.

Frickhofen N , Chen ZJ , Young NS , Cohen BJ , Hempel H , Abrowitz JL . Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol 1994; 87: 818–24.

Socinski MA , Ershler WB , Tosato G , Blaese RM . Pure red blood cell aplasia associated with chronic Epstein–Barr virus infection: evidence for T cell-mediated suppression of erythroid colony forming units. J Lab Clin Med 1984; 104:995–1006.

Krantz SB , Kao V . Studies on red cell aplasia. I. Demonstration of a plasma inhibitor to heme synthesis and an antibody to erythroblast nuclei. Proc Natl Acad Sci USA 1967; 58:493–500.

Jepson JH , Lowenstein L . Panhypoplasia of the bone marrow. Demonstration of a plasma factor with anti-erythropoietin-like activity. Can Med Assoc J 1968; 99: 99–101.

Peschle C , Marmont AM , Marone G , Genovese A , Saso GF , Condorelli M . Pure red cell aplasia: studies on an IgG serum inhibitor neutralizing erythropoietin. Br J Haematol 1975; 30:411–17.

Messner HA , Fauser AA , Curtis JE , Dotten D . Control of antibody-mediated pure red-cell aplasia by plasmapheresis. N Engl J Med 1981; 304:1334–8.

Casadevall N , Dupuy E , Molho–Sabatier P , Tobelem G , Varet B , Mayeux P . Autoantibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996; 334:630–3.

Bergrem H , Danielson BG , Eckardt KU , Kurtz A , Stridsberg M . A case of antierythropoietin antibodies following recombinant human erythropoietin treatment. In: Bauer C , Koch KM , Scigalla P , Wieczorek L , eds. Erythropoietin: Molecular Physiology and Clinical Application. New York: Marcel Dekker; 1993: 266–75.

Peces R , de la Torre M , Alcazar R , Urra J . Antibodies against recombinant human erythropoietin in a patient with erythropoietin resistant anemia. N Engl J Med 1996; 335:523–4.

Prabhakar SS , Muhlfelder T . Antibodies to recombinant human erythropoietin causing pure red cell aplasia. Clin Nephrol 1997; 47:331–5.

Casadevall N , Nataf J , Viron B , Kolta A , Kiladjian JJ , Martin–Dupont P . Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469–75.

Casadevall N . Antibodies against rHuEPO: native and recombinant. Nephrol Dial Transplant 2002; 17(Suppl 5):42–7.

Castelli G , Famularo A , Semino C , Machi AM , Ceci A , Cannella G . Detection of anti-erythropoietin antibodies in haemodialysis patients treated with recombinant human-erythropoietin. Pharmacol Res 2000; 41: 313–18.

Recny M , Scoble HA , Kim Y . Structural characterization of natural human erythropoietin. J Biol Chem 1987; 363:17156–63.

Ersler AJ . Erythropoietin. N Engl J Med 1991; 324: 1338–41.